Literature DB >> 24971685

Navigable intraoperative ultrasound and fluorescence-guided resections are complementary in resection control of malignant gliomas: one size does not fit all.

Aliasgar Moiyadi1, Prakash Shetty1.   

Abstract

INTRODUCTION: Conventional imaging (intraoperative ultrasound and intraoperative magnetic resonance imaging) as well as enhanced visualization (aminolevulinic acid [ALA]-based fluorescence-guided resection) have both been used to improve the resection of malignant gliomas. Each modality has its pros and cons and may not be suitable for all cases. We describe our experience with these two complementary techniques.
METHODS: Eight patients underwent resection for malignant gliomas using combined navigable three-dimensional ultrasound (3D-US) and ALA-induced fluorescence. These were analyzed for magnetic resonance imaging characteristics, resectability, and extent of resection. The utility of navigable 3D-US and the fluorescence were assessed for each case to stratify cases that may benefit from either or both of these techniques.
RESULTS: Four subjects had predominant contrast-enhancing potentially resectable gliomas. Intraoperative strong fluorescence was seen, which was the primary guide for resection control. Navigable 3D-US was additionally useful for planning the craniotomy and localizing the subcortical lesions. All four tumors were gross-totally excised. Four other tumors were minimally enhancing and diffuse. Fluorescence was patchy and not used for resection control; instead, navigable 3D-US was the primary guide for resection. However, the fluorescence helped locating the focally higher grade parts within the tumors. Gross-total resection could be achieved in one patient.
CONCLUSIONS: Navigable 3D-US and ALA-induced fluorescence provide information regarding different aspects of tumor extent and combined together enhance the extent of resection. Fluorescence-guided resection may be sufficient for enhancing tumors, but nonenhancing tumors are better resected with navigable 3D-US. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24971685     DOI: 10.1055/s-0034-1372436

Source DB:  PubMed          Journal:  J Neurol Surg A Cent Eur Neurosurg        ISSN: 2193-6315            Impact factor:   1.268


  6 in total

1.  Gliomas: Motexafin Gadolinium-enhanced Molecular MR Imaging and Optical Imaging for Potential Intraoperative Delineation of Tumor Margins.

Authors:  Longhua Qiu; Feng Zhang; Yaoping Shi; Zhibin Bai; Jianfeng Wang; Yonggang Li; Donghoon Lee; Christopher Ingraham; Xiaoyuan Feng; Xiaoming Yang
Journal:  Radiology       Date:  2015-11-24       Impact factor: 11.105

Review 2.  Applications of Ultrasound in the Resection of Brain Tumors.

Authors:  Rahul Sastry; Wenya Linda Bi; Steve Pieper; Sarah Frisken; Tina Kapur; William Wells; Alexandra J Golby
Journal:  J Neuroimaging       Date:  2016-08-19       Impact factor: 2.486

Review 3.  Various shades of red-a systematic analysis of qualitative estimation of ALA-derived fluorescence in neurosurgery.

Authors:  Marcel A Kamp; Zarela Krause Molle; Christopher Munoz-Bendix; Marion Rapp; Michael Sabel; Hans-Jakob Steiger; Jan F Cornelius
Journal:  Neurosurg Rev       Date:  2016-05-25       Impact factor: 3.042

4.  Intraoperative fluorescence diagnosis in the brain: a systematic review and suggestions for future standards on reporting diagnostic accuracy and clinical utility.

Authors:  Walter Stummer; Raphael Koch; Ricardo Diez Valle; David W Roberts; Nadar Sanai; Steve Kalkanis; Constantinos G Hadjipanayis; Eric Suero Molina
Journal:  Acta Neurochir (Wien)       Date:  2019-07-30       Impact factor: 2.216

Review 5.  Current Limitations of Intraoperative Ultrasound in Brain Tumor Surgery.

Authors:  Andrej Šteňo; Ján Buvala; Veronika Babková; Adrián Kiss; David Toma; Alexander Lysak
Journal:  Front Oncol       Date:  2021-03-22       Impact factor: 6.244

6.  Novel Multimodal, Multiscale Imaging System with Augmented Reality.

Authors:  Christopher Mela; Francis Papay; Yang Liu
Journal:  Diagnostics (Basel)       Date:  2021-03-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.